CHALLENGE 10
Measuring Pipeline Activity Instead of Commercial Readiness
A Health IT company can have a large pipeline, a busy sales team, frequent demos, positive prospect feedback, and a growing number of proposals—and still have very little predictable revenue.
The reason is that pipeline activity and buyer progress are not the same thing.
A meeting happened.
A demo was completed.
A proposal was sent.
A pilot is being discussed.
The prospect said they liked the solution.
Those are useful events, but none proves that the provider is actually moving toward a buying decision.
Commercial readiness requires evidence that the problem matters, the right stakeholders are engaged, the business case works, risk is understood, the Decision Process is moving, and the provider is committing resources toward action.
A healthy pipeline is not a collection of interested prospects. It is a collection of buyers demonstrating evidence that they are moving toward a decision.
Seller’s Lens vs. Buyer’s Lens
Sales organizations naturally measure what their teams are doing. Providers reveal commercial readiness through what the buying organization is doing in response.
Seller’s Lens
“The deal is moving.”
The seller sees:
- another meeting scheduled;
- a successful demo;
- positive stakeholder feedback;
- a proposal requested;
- a pilot being discussed;
- additional contacts engaged;
- an opportunity advancing in the CRM;
- and an expected close date on the forecast.
From the seller’s perspective, activity creates the appearance of momentum.
Buyer’s Lens
“Are we actually moving toward a decision?”
The provider demonstrates:
- increasing urgency around the problem;
- involvement of additional decision-makers;
- validation of the financial case;
- commitment of internal resources;
- progress through security and governance;
- agreement on Decision Criteria;
- movement through the Decision and Paper Processes;
- and clear actions that reduce the likelihood of doing nothing.
Seller activity shows that the opportunity is active. Buyer evidence shows whether it is advancing.
Why This Becomes a GTM Problem
When pipeline management rewards activity rather than buyer evidence, opportunities can remain artificially healthy long after the provider has stopped making meaningful progress toward a decision.
Meetings Are Mistaken for Momentum
The calendar stays busy, but each conversation produces little new evidence about the buying decision.
A Proposal Becomes a Buying Signal
The seller interprets a request for pricing or documentation as proof that the provider intends to purchase.
Positive Feedback Inflates Confidence
Stakeholders like the technology, but no one has committed resources, funding, or political capital to moving forward.
CRM Stages Outrun Buyer Progress
The opportunity advances because seller activities occurred rather than because buyer commitments were demonstrated.
Close Dates Keep Moving
The forecast changes month after month because the date reflects seller hope rather than the provider’s Decision Process.
"No Decision" Is Underestimated
The team focuses on named competitors while the provider’s easiest alternative—doing nothing—remains insufficiently challenged.
An opportunity can remain busy for months without becoming more buyable.
Lessons From the Field
Activity Is Easy to Measure. Buyer Commitment Is Harder.
CRMs make it easy to count calls, meetings, demos, proposals, and opportunities.
Those metrics can be useful for understanding sales activity.
But they do not answer whether the buyer is becoming more committed to making a decision.
The stronger questions are:
What has the provider done?
What has changed internally?
Who has become involved?
What resources have been committed?
What uncertainty has been removed?
The most important pipeline evidence often comes from the buyer’s actions, not the seller’s activity.
Lessons From the Field
A Proposal Is Not Proof of Intent
Sales teams understandably become more confident when a prospect requests a proposal.
But providers may request pricing for budgeting, benchmarking, internal evaluation, comparison, or simply to understand the size of the potential investment.
A proposal becomes commercially meaningful when it sits inside a known Decision Process with agreed criteria, stakeholders, timing, and next actions.
Sending a proposal proves the seller completed a step. It does not prove the buyer made a commitment.
Lessons From the Field
“No Decision” Is a Competitor
A Health IT company may spend significant time preparing competitive positioning against other vendors while underestimating the most common alternative:
Do nothing.
If the Pain is not important enough, the business case is weak, organizational risk remains unresolved, or priorities shift, the provider may simply keep the status quo.
That is why Competition in MEDDPICC® includes more than named competitors.
The deal does not have to be lost to another vendor to be lost.
How to Diagnose Commercial Readiness
Separate Activity From Evidence
For every major sales activity, ask what buyer evidence it produced.
Seller Activity
- demo completed;
- meeting held;
- proposal sent;
- security documents delivered;
- pilot discussed.
Buyer Evidence
- Pain was quantified;
- Champion provided internal access;
- Economic Buyer engaged;
- Decision Criteria clarified;
- business case validated;
- security requirements identified;
- Decision Process mapped;
- next decision agreed.
The activity may be necessary.
The evidence tells you whether it mattered.
Do not ask only, “What happened?” Ask, “What did we learn or prove about the buyer?”
Build Pipeline Stages Around Buyer Commitments
Pipeline stages become more reliable when they represent a meaningful change in the provider’s buying process.
An opportunity should not advance simply because:
a demo happened.
It should advance because the demo resulted in buyer evidence required for the next stage.
That might include:
- the problem has been validated;
- measurable impact is understood;
- a Champion is identified;
- additional stakeholders are engaged;
- financial assumptions are accepted;
- Decision Criteria are known;
- the Decision Process is mapped;
- or the Paper Process has begun.
The strongest stage exit criteria describe what the buyer has demonstrated—not what the seller has completed.
Forecast From the Provider’s Decision Process
A seller may want the deal to close this quarter.
That is not a forecast methodology.
A credible close date should reflect:
- when the provider expects to make the decision;
- what approvals remain;
- when the Economic Buyer engages;
- security and governance timing;
- procurement requirements;
- contracting steps;
- budget availability;
- and dependencies outside the seller’s control.
If those milestones cannot support the expected close date, the forecast should change before the calendar forces it to.
A close date should be derived from the buyer’s process—not reverse-engineered from the seller’s quota period.
Use MEDDPICC® as Evidence, Not Administration
MEDDPICC® becomes valuable when it helps the sales team test what it actually knows about the opportunity.
Not whether fields have been completed.
But whether meaningful evidence exists around:
- Metrics
- Economic Buyer
- Decision Criteria
- Decision Process
- Paper Process
- Identified Pain
- Champion
- Competition
A field marked “complete” does not qualify a deal.
The quality of the evidence does.
MEDDPICC® should expose uncertainty in the deal—not hide it behind completed CRM fields.
Commercial Readiness — Bottom Line
Commercial readiness is not measured by how much activity surrounds an opportunity. It is measured by the accumulating buyer evidence that makes a decision increasingly likely.
Better Discovery Questions — Don’t Ask / Ask Instead
Good pipeline management does not simply ask what happened since the last call. It asks what changed in the buyer’s ability and willingness to make a decision.
DON’T ASK
“How did the meeting go?”
ASK INSTEAD
“What did the buyer do or tell us that increases—or decreases—our confidence that they are moving toward a decision?”
DON’T ASK
“When do you think this will close?”
ASK INSTEAD
“What remaining provider decisions and approvals support that expected close date?”
DON’T ASK
“What’s our next step?”
ASK INSTEAD
“What is the buyer’s next decision, and what evidence must exist for them to make it?”
The objective is not to keep the opportunity moving. It is to determine whether the buyer is moving.
From Pipeline Activity to Commercial Readiness
Before treating an active opportunity as a qualified opportunity, the sales team should be able to show evidence that the provider is progressively reducing uncertainty, committing resources, involving the right stakeholders, and moving through a recognizable Decision Process. The Buyer’s-Lens Test helps separate pipeline motion from genuine buying momentum.
1. Questions Health IT Companies Should Be Able to Answer
☐ Is the Pain important enough to act on now?
☐ Have meaningful Metrics been established?
☐ Is there a tested Champion?
☐ Is the Economic Buyer known?
☐ Are the Decision Criteria understood?
☐ Is the business case validated by the provider?
☐ Is the Decision Process mapped?
☐ Is the Paper Process understood?
☐ Are security and governance requirements progressing?
☐ What buyer commitments have occurred?
☐ What could still result in no decision?
☐ Does the provider’s process support the forecasted close date?
If the opportunity has significant activity but these answers remain vague, the pipeline stage may be overstating commercial readiness.
The Buyer’s-Lens Test
A commercially ready opportunity should allow the sales team to answer “yes” to each of the following:
✓ Yes, the provider has a compelling reason to act.
The Pain and consequences of doing nothing are understood.
✓ Yes, the right people are participating.
The Champion, Economic Buyer, and critical stakeholders are visible.
✓ Yes, the provider has validated the value.
Metrics, economics, workflow, risk, and expected outcomes support the decision.
✓ Yes, we understand how the decision will happen.
Decision Criteria, Decision Process, and Paper Process are mapped.
✓ Yes, the buyer is demonstrating commitment.
Actions—not simply positive words—show that the organization is moving toward purchase.
When those five answers are present, the pipeline is no longer being qualified by activity. It is being qualified by buyer evidence.
David's GTM Takeaway
A large pipeline feels reassuring.
It creates activity.
It generates forecasts.
It gives leadership numbers to discuss.
But pipeline volume does not create revenue unless the opportunities inside it contain buyers who are actually progressing toward decisions.
That means sales leadership needs to look beyond demos, meetings, proposals, stages, and close dates.
Ask what the buyer has done.
Ask what evidence has changed.
Ask what remains unknown.
Ask what could still cause no decision.
Use MEDDPICC® to expose the gaps.
Use stage exit criteria to prevent seller activity from masquerading as buyer progress.
And forecast from the provider’s Decision Process—not the seller’s desired close date.
A healthy pipeline is not a collection of interested prospects. It is a collection of buyers demonstrating evidence that they are moving toward a decision.